Clinical Cancer Research · 2006 · 150 citations · 23 references
MedicineCancer BiologyOncologyBreast OncologyGene ExpressionMolecular OncologyBreast Cancer OncologyCancer BiomarkersTumor AntigensBreast Cancer PrognosisClinicopathologic FeaturesEstrogen Receptor StatusImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingPrognostic VariablesTumor Differentiation Assessment
PURPOSE: We aimed to evaluate the expression of the human anterior gradient-2 (AGR2) in breast cancer on RNA and protein level and to correlate it with clinicopathologic data, including patient survival. EXPERIMENTAL DESIGN: AGR2 mRNA expression was assessed by reverse transcription-PCR in 25 breast cancer samples and normal tissues. A polyclonal rabbit AGR antiserum was used for immunohistochemistry on 155 clinicopathologically characterized cases. Statistical analyses were applied to test for prognostic and diagnostic associations. RESULTS: Immunohistochemical detection of AGR2 was statistically significantly associated with positive estrogen receptor status and lower tumor grade. AGR2-positive tumors showed significantly longer overall survival times in univariate analyses. For the subgroup of nodal-negative tumors, an independent prognostic value of AGR2 was found. CONCLUSIONS: The expression of AGR2 in breast cancer is strongly associated with markers of tumor differentiation (estrogen receptor positivity, lower tumor grade). A prognostic effect of AGR2 for overall survival could be shown, which became independently significant for the group of nodal-negative tumors.
23
TNM Classification of Malignant Tumors
Darryl Carter · The American Journal of Surgical Pathology · 1998 · 6.4K citations
TNM classification of malignant tumors, fifth edition (1997)
Leslie H. Sobin, Irvin D. Fleming · Cancer · 1997 · 1K citations
Real-time quantitative RT–PCR after laser-assisted cell picking
Ludger Fink, Werner Seeger, Leander Ermert et al. · Nature Medicine · 1998 · 565 citations
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Patrick C. Walsh · PubMed · 2002 · 477 citations